How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,699 results for

Intrauterine Device

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Routine Pathology for Intrauterine Devices and Therapeutic Abortion: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Routine Pathology for Intrauterine Devices and Therapeutic Abortion: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Routine Pathology for Intrauterine Devices and Therapeutic Abortion: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Routine Pathology for Intrauterine Devices and Therapeutic Abortion: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Routine Pathology for Intrauterine (...) Devices and Therapeutic Abortion: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: September 12, 2019 Project Number: RC1176-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical utility of routine pathology for removed intrauterine devices? What is the clinical utility of routine pathology for therapeutic abortions? What is the cost-effectiveness of routine pathology

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Intrauterine Devices and Magnetic Resonance Imaging: Safety

Intrauterine Devices and Magnetic Resonance Imaging: Safety Intrauterine Devices and Magnetic Resonance Imaging: Safety | CADTH.ca Find the information you need Intrauterine Devices and Magnetic Resonance Imaging: Safety Intrauterine Devices and Magnetic Resonance Imaging: Safety Published on: March 28, 2017 Project Number: RB1074-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical evidence regarding the safety (...) of patients with intrauterine devices using magnetic resonance imaging? Key Message No relevant literature was identified regarding the safety of patients with intrauterine devices using magnetic resonance imaging. Tags copper, intrauterine devices, intrauterine devices, copper, magnetic resonance imaging, imaging, IUD, Intrauterine, metal, Adverse, safe, MRI, MRIs, Magnetic resonance imaging Files Rapid Response Summary of Abstracts Published : March 28, 2017 Related Content Follow us: © 2019 Canadian

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Adolescents and Long-Acting Reversible Contraception: Implants and Intrauterine Devices

Adolescents and Long-Acting Reversible Contraception: Implants and Intrauterine Devices e130 VOL. 131, NO. 5, MAY 2018 OBSTETRICS & GYNECOLOGY Adolescents and Long-Acting Reversible Contraception: Implants and Intrauterine Devices ABSTRACT: The phenomenon of adolescent childbearing is complex and far reaching, affecting not only the adolescents but also their children and their community. The prevalence and public health effect of adolescent pregnancy reflect complex structural social problems (...) and an unmet need for acceptable and effective contra- ceptive methods in this population. In 2006–2010, 82% of adolescents at risk of unintended pregnancy were currently using contraception, but only 59% used a highly effective method, including any hormonal method or intrauterine device. Long-acting reversible contraceptives (LARC) have higher efficacy, higher continuation rates, and higher satisfaction rates compared with short-acting contraceptives among adolescents who choose to use them

2018 American College of Obstetricians and Gynecologists

5. Use of intrauterine devices in nulliparous women

Use of intrauterine devices in nulliparous women Clinical Guidelines Use of intrauterine devices in nulliparous women Patricia A. Lohr a, ? , Richard Lyus b , Sarah Prager c a British Pregnancy Advisory Service, 20 Timothy's Bridge Road, Stratford Enterprise Park, Stratford on Avon, Warwickshire, CV37 9BF b Homerton University Hospital, London c University of Washington Received 18 August 2017; accepted 23 August 2017 Abstract Five intrauterine devices (IUDs) are available in the United States (...) : four levonorgestrel-releasing intrauterine systems (two containing 52 mg, one containing 19.5 mg and one containing 13.5 mg) and one copper-bearing device (Copper T 380A). All IUDs have very low typical- use failure rates and high acceptability ratings, yet they are used by a minority of women, with nulliparous women less likely to do so than parous women. The objective of this clinical review is to give evidence-based recommendations for the use of IUDs in nulliparous women

2017 Society of Family Planning

6. Postplacental insertion of intrauterine devices

Postplacental insertion of intrauterine devices Review article Society of Family Planning Guidelines: Postplacental insertion of intrauterine devices Amy K. Whitaker a, ? , Beatrice A. Chen b a Department of Obstetrics and Gynecology, The University of Chicago, 5842 S. Maryland Ave, Chicago, IL 60637, USA b Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, 300 Halket Street, Pittsburgh, PA 15213, USA Received 3 June 2017; revised 27 (...) for the postpartum visit are most likely to benefit from provision of postplacental IUD placement with appropriate counseling about risks and benefits. © 2017 Elsevier Inc. All rights reserved. Keywords: Postpartum contraception; Intrauterine device; Intrauterine system; Contraception; Levonorgestrel; Postplacental IUD; Postpartum IUD; IUD expulsion 1. Background Intrauterine device (IUD) placement within 10 min after delivery of the placenta is an appealing strategy for increasing access to postpartum IUDs

2017 Society of Family Planning

7. Long-Acting Reversible Contraception: Implants and Intrauterine Devices

Long-Acting Reversible Contraception: Implants and Intrauterine Devices Long-Acting Reversible Contraception: Implants and Intrauterine Devices - ACOG Menu ▼ Long-Acting Reversible Contraception: Implants and Intrauterine Devices Page Navigation ▼ Number 186, November 2017 (Replaces Practice Bulletin Number 121, July 2011) Committee on Practice Bulletins—Gynecology . This Practice Bulletin was developed by the Committee on Practice Bulletins—Gynecology and the Long-Acting Reversible (...) , incurred in connection with this publication or reliance on the information presented. Long-Acting Reversible Contraception: Implants and Intrauterine Devices Intrauterine devices and contraceptive implants, also called long-acting reversible contraceptives (LARC), are the most effective reversible contraceptive methods. The major advantage of LARC compared with other reversible contraceptive methods is that they do not require ongoing effort on the part of the patient for long-term and effective use

2017 American College of Obstetricians and Gynecologists

8. Intrauterine mepivacaine instillation for pain relief during intrauterine device insertion in nulliparous women: a double-blind randomized controlled trial. (PubMed)

Intrauterine mepivacaine instillation for pain relief during intrauterine device insertion in nulliparous women: a double-blind randomized controlled trial. To evaluate whether intrauterine mepivacaine instillation before intrauterine device (IUD) insertion decreases pain compared to placebo.We performed a double-blind, randomized, controlled trial comparing mepivacaine 1%, 10ml versus 0.9% NaCl intrauterine instillation using a hydrosonography catheter 5min before IUD insertion in women (...) insertion was 4.8cm in the intervention group (n=41, IQR=3.1-5.8) and 5.9cm in the placebo group (n=40, IQR=3.3-7.5, p=.062). In the per protocol analysis, the median VAS with IUD insertion was 4.8cm (IQR=3.1-5.5) and 6.0cm (IQR=3.4-7.6) for the intervention and placebo groups respectively (p=.033). More women in the intervention group reported the procedure as easier than expected (n=26, 63.4% vs. n=15, 37.5%) and fewer reported it as worse than expected (n=3, 7.3% vs. n=14, 35%, p=.006).Intrauterine

Full Text available with Trip Pro

2019 Contraception Controlled trial quality: predicted high

9. Effects of a levonorgestrel intrauterine system versus a copper intrauterine device on menstrual changes and uterine artery Doppler. (PubMed)

Effects of a levonorgestrel intrauterine system versus a copper intrauterine device on menstrual changes and uterine artery Doppler. To compare the effects of a levonorgestrel-releasing intrauterine system (LNG-IUS) and a copper intrauterine device (Cu-IUD) on menstrual changes and uterine artery Doppler indices.A randomized clinical trial was conducted at Menoufia University Hospital, Egypt, between December 2016 and August 2017. 306 multiparous women desiring intrauterine contraception were

2019 International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics Controlled trial quality: uncertain

10. New Crosslinked Hyaluronan Gel, Intrauterine Device, or Both for the Prevention of Intrauterine Adhesions. (PubMed)

New Crosslinked Hyaluronan Gel, Intrauterine Device, or Both for the Prevention of Intrauterine Adhesions. To compare the efficacy of 3 different techniques for prevention of adhesion reformation after hysteroscopic adhesiolysis in patients with moderate-to-severe intrauterine adhesions. Short-term assisted reproductive outcomes were also compared.Total of 72 cases were randomized to Lippes loop intrauterine device (IUD) only, IUD plus a new crosslinked hyaluronan (NCH) gel, or NCH gel only (...) difference.All interventions are of similar efficacy in the prevention of adhesion reformation after hysteroscopic adhesiolysis for moderate to severe intrauterine adhesions. However, better endometrial thickness values were observed in those who received NCH gel either alone or in combination with IUD. Assisted reproductive outcomes of both groups were comparable for ongoing pregnancy rates.

2019 JSLS : Journal of the Society of Laparoendoscopic Surgeons Controlled trial quality: uncertain

11. A prospective, randomized study evaluating the pain felt during intrauterine device insertion by the direct technique vs conventional technique. (PubMed)

A prospective, randomized study evaluating the pain felt during intrauterine device insertion by the direct technique vs conventional technique. To assess the value of the direct insertion technique compared to the conventional insertion technique in reducing the pain experienced during placement of an intrauterine device (IUD).A prospective, controlled, randomized, single-blind trial was conducted in women eligible for IUD insertion. Participants were randomized into two groups: "conventional

2019 Journal of gynecology obstetrics and human reproduction Controlled trial quality: uncertain

12. Effect of topical glyceryl trinitrate cream on pain perception during intrauterine device insertion in multiparous women: A randomized double-blinded placebo-controlled study. (PubMed)

Effect of topical glyceryl trinitrate cream on pain perception during intrauterine device insertion in multiparous women: A randomized double-blinded placebo-controlled study. Intrauterine contraceptive device (IUD) insertion-related pain presents a push beyond the decline of women to use IUD for family planning. We aimed to investigate the analgesic effect of glyceryl trinitrate cream (GTN) in reducing pain during IUD insertion.We conducted a randomized double-blinded placebo-controlled study

2019 Journal of gynecology obstetrics and human reproduction Controlled trial quality: predicted high

13. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. (PubMed)

HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Observational and laboratory studies suggest that some hormonal contraceptive methods, particularly intramuscular depot medroxyprogesterone acetate (DMPA-IM), might increase women's susceptibility to HIV acquisition. We aimed to compare DMPA-IM, a copper intrauterine device (IUD (...) ), and a levonorgestrel (LNG) implant among African women seeking effective contraception and living in areas of high HIV incidence.We did a randomised, multicentre, open-label trial across 12 research sites in eSwatini, Kenya, South Africa, and Zambia. We included HIV-seronegative women aged 16-35 years who were seeking effective contraception, had no medical contraindications to the trial contraceptive methods, agreed to use the assigned method for 18 months, and reported not using injectable, intrauterine

2019 Lancet Controlled trial quality: predicted high

14. Self-administered vaginal lidocaine gel for pain management with intrauterine device insertion: a blinded, randomized controlled trial

Self-administered vaginal lidocaine gel for pain management with intrauterine device insertion: a blinded, randomized controlled trial A major barrier to intrauterine device use is fear of pain during insertion. Trials exploring analgesic interventions for intrauterine device insertion have yielded mixed results, and no standardized pain management guidelines currently exist for this procedure. In an abortion-related study, self-administered lidocaine gel over a prolonged time interval showed (...) promise as a method of pain control.The objective of the study was to assess pain control with intrauterine device insertion after patient-administered lidocaine gel compared with placebo.We conducted a randomized, blinded trial of women undergoing levonorgestrel or copper intrauterine device insertion in an outpatient gynecology clinic between July 2016 and April 2017. Participants self-administered either 20 mL of 2% lidocaine gel or placebo gel vaginally at least 15 minutes prior to intrauterine

Full Text available with Trip Pro

2019 EvidenceUpdates

15. Providers' knowledge on postpartum intrauterine contraceptive device (PPIUCD) service provision in Amhara region public health facility, Ethiopia. (PubMed)

Providers' knowledge on postpartum intrauterine contraceptive device (PPIUCD) service provision in Amhara region public health facility, Ethiopia. Postpartum intrauterine contraceptive devices (PP-IUCD) are one type of post-partum family planning method, which can be provided to a post-partum woman starting from the placental delivery time (within 10 minutes), or within the first 48 hours of postpartum period. In most developing countries, delivery time is the primary opportunity for women (...) to access post-partum family planning methods, especially for those living in remote areas. Hence, this study assesses providers' knowledge on postpartum intrauterine contraceptive device service provision.A facility-based cross-sectional study was conducted in Amhara region health center and hospitals. Health providers surveyed included obstetricians, gynecologists, general practitioners, emergency surgical officers, health officers, midwives and nurses from September 18, 2015 to December18, 2016

Full Text available with Trip Pro

2019 PLoS ONE

16. Hysteroscopic Intrauterine Morcellation for Benign Intrauterine Pathologies: Clinical Effectiveness and Guidelines

and Guidelines Last updated: October 23, 2018 Project Number: RB1267-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of hysteroscopic intrauterine morcellation for the removal of benign intrauterine pathologies? What are the evidence-based guidelines regarding the management of an unsuspected malignancy diagnosed in patients who have previously undergone hysteroscopic intrauterine morcellation (...) Hysteroscopic Intrauterine Morcellation for Benign Intrauterine Pathologies: Clinical Effectiveness and Guidelines Hysteroscopic Intrauterine Morcellation for Benign Intrauterine Pathologies: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Hysteroscopic Intrauterine Morcellation for Benign Intrauterine Pathologies: Clinical Effectiveness and Guidelines Hysteroscopic Intrauterine Morcellation for Benign Intrauterine Pathologies: Clinical Effectiveness

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

17. Bleeding pattern difference between levonorgestrel-intrauterine system and copper-intrauterine devices inserted immediately post-abortion: a multicenter, prospective, observational cohort study in Chinese women. (PubMed)

Bleeding pattern difference between levonorgestrel-intrauterine system and copper-intrauterine devices inserted immediately post-abortion: a multicenter, prospective, observational cohort study in Chinese women. To describe the bleeding pattern (primary outcome), side effects, treatment satisfaction and 6 month continuity rates associated with the 52 mg levonorgestrel intrauterine system (LNG-IUS) and the copper intrauterine device (Cu-IUD) inserted immediately after abortion.This multicenter

2018 Current medical research and opinion

18. Interventions for pain with intrauterine device insertion. (PubMed)

Interventions for pain with intrauterine device insertion. Fear of pain during insertion of intrauterine contraception (IUC) is a barrier to use of this method. IUC includes copper-containing intrauterine devices and levonorgestrel-releasing intrauterine systems. Interventions for pain control during IUC insertion include non-steroidal anti-inflammatory drugs (NSAIDs), local cervical anesthetics, and cervical ripening agents such as misoprostol.To review randomized controlled trials (RCTs

Full Text available with Trip Pro

2015 Cochrane

19. Immediate postpartum insertion of intrauterine device for contraception. (PubMed)

Immediate postpartum insertion of intrauterine device for contraception. Women who want to start intrauterine contraception (IUC) during the postpartum period might benefit from IUC insertion immediately after delivery. Postplacental insertion greatly reduces the risk of subsequent pregnancy and eliminates the need for a return visit to start contraception. Without the option of immediate insertion, many women may never return for services or may adopt less effective contraception.Our aim (...) sensitivity analysis included trials with sufficient outcome data and moderate or high quality evidence. Four newer trials comparing insertion times met the inclusion criteria. Two studies used the levonorgestrel-releasing intrauterine system (LNG-IUS) after vaginal delivery. The other two trials placed IUC after cesarean section; one used the CuT 380A intrauterine device (IUD) and the other used the LNG-IUS.A pilot trial compared immediate insertion versus early or standard insertion. In groups comparing

Full Text available with Trip Pro

2015 Cochrane

20. Immediate postabortal insertion of intrauterine devices. (PubMed)

Immediate postabortal insertion of intrauterine devices. Background The use of an effective contraceptive may be necessary after an abortion. Insertion of an intrauterine device (IUD) may be done the same day or later. Immediate IUD insertion is an option since the woman is not pregnant, pain of insertion is less because the cervical os is open, and her motivation to use contraception may be high. However, insertion of an IUD immediately after a pregnancy ends carries risks, such as spontaneous (...) participants); the quality of evidence was moderate. Moderate quality of evidence also suggests that use and expulsion of levonorgestrel-releasing intrauterine system or CuT380A was more likely for immediate compared to delayed insertion risk ratio (RR) 1.40 (95% CI 1.24 to 1.58; 3 studies; 878 participants) and RR 2.64 ( 95% CI 1.16 to 6.00; 3 studies; 878 participants) respectively. Another trial randomised to the levonorgestrel IUD or Nova T showed discontinuation rates due to pregnancy were likely

Full Text available with Trip Pro

2014 Cochrane

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>